Russian-made Vital Drugs May Disappear From The Shelves

Table of contents:

Russian-made Vital Drugs May Disappear From The Shelves
Russian-made Vital Drugs May Disappear From The Shelves

Video: Russian-made Vital Drugs May Disappear From The Shelves

Отличия серверных жестких дисков от десктопных
Video: Russia's New Weapon in Ukraine: Offering Citizenship 2023, January
Anonim

Russian-made vital drugs may disappear from the shelves

The COVID-19 pandemic and the devaluation of the ruble have dealt a double blow to the domestic pharmaceutical industry.

Russian-made vital drugs may disappear from the shelves
Russian-made vital drugs may disappear from the shelves

Photo: CC0 Public Domain

The largest drug manufacturers in Russia may abandon the production of a number of vital drugs (VED) due to unprofitability amid the devaluation of the ruble and the rise in import prices. According to Kommersant, market participants have already warned the Ministry of Industry and Trade that they may abandon the production of 50 popular drugs, including paracetomol, diphenhydramine and ibuprofen. A warning letter was sent to the department by seven pharmaceutical companies, including Dalkhimpharm, Ozon Pharmaceuticals, Biosintez, as well as one of the largest market players Pharmstandard.

In their appeal to the Ministry of Industry and Trade, manufacturers indicated that today the maximum allowable price for a package of paracetamol of 20 tablets in a dosage of 0.5 g, produced by Biosynthez, is 10.1 rubles. At the same time, the cost of production is at the level of 16.46 rubles. The price of a package of 20 ibuprofen tablets with a dosage of 200 mg should not exceed 12.05 rubles, while production costs Biosintez now 17.21 rubles. The difficult situation in the pharmaceutical industry is exacerbated by an increase in the demand and cost of imported substances against the backdrop of a pandemic and the devaluation of the ruble. In particular, the price of the substance ibuprofen increased from $ 22.3 to $ 28 per 1 kg, and paracetamol - from $ 4.7 to $ 5.8. Biosynthesis has already suspended the production of these drugs.

At the same time, prices for vital drugs were registered in 2009, when the average values ​​provided by the manufacturers themselves based on the results of last year's sales were taken as the basis. Local companies were given the opportunity to be indexed annually to the inflation rate, but not more than by 6%.

After the devaluation of the ruble in 2014, some drugs have already left the Russian market due to the unprofitable circulation, pharmaceutical manufacturers say. There is a real threat that it will happen again.

Kommersant also notes that the new pricing methodology for vital drugs, according to which their manufacturers must re-register prices by the end of 2020, was adopted in 2019. She assumed that the cost of the so-called innovative drugs should not exceed their cost in a number of other countries, and the price of analogues would be registered with a decreasing coefficient. This approach suited the market players until a rule was added to it that new prices cannot exceed existing ones, as a result of which manufacturers are forced to re-register prices at lower ones.

Popular by topic